- Home
- VALN
VALN
Valneva SE
as 11-05-2025 4:00pm EST
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
| Founded: | 2012 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 820.0M | IPO Year: | 2021 |
| Target Price: | $15.75 | AVG Volume (30 days): | 26.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.62 - $12.25 | Next Earning Date: | 11-20-2025 |
| Revenue: | $230,566,060 | Revenue Growth: | 25.47% |
| Revenue Growth (this year): | 6.86% | Revenue Growth (next year): | 11.85% |
Latest Valneva SE News
VALN Breaking Stock News: Dive into VALN Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Barrons.com
2 months ago
A Lyme Disease Vaccine’s Final Test Results Could Appear By Yearend.
MT Newswires
4 months ago
Valneva Signs Vaccine Distribution Deal With CSL Seqirus in Germany
GlobeNewswire
4 months ago
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
GlobeNewswire
4 months ago
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
TipRanks
5 months ago
UK restricts use of Valneva chikungunya vaccine for safety review
Clinical Trials Arena
5 months ago
Valneva reports data from Phase II chikungunya vaccine trial in children
GlobeNewswire
5 months ago
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
Compare VALN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VALN Valneva SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.